我们认为可以通过对其他前50家药企销售额小额征税的方式设立有效的市场准入奖励，因为这其他50家制药企业并没有承担他们应尽的义务。
We determined that an effective market-entry reward could be funded by small levies on the sales of the other top-50 pharmaceutical firms that are not carrying their weight.